Literature DB >> 6859835

In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus.

M Maduri Traczewski, D A Goldmann, P Murphy.   

Abstract

The in vitro activity of rifampin alone and in combination with oxacillin was determined for 75 Staphylococcus aureus strains (64 susceptible and 11 resistant to oxacillin). Minimal inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) were determined by broth microdilution; antibiotic combinations were evaluated by microdilution checkerboard and time-kill studies. The 90% MIC of rifampin was less than or equal to 0.015 micrograms/ml after both 24 and 48 h of incubation. The 90% MBC of rifampin was less than or equal to 2.0 micrograms/ml on subculture at 24 h of incubation and less than or equal to 0.5 micrograms/ml on subculture at 48 h. MIC checkerboards with oxacillin-susceptible strains revealed an additive or indifferent effect in 35 strains (55%) and antagonism in 29 strains (45%). MBC checkerboards performed by subculture at 24 h demonstrated antagonism for all but one of the oxacillin-susceptible strains, with sub-MBCs of rifampin impairing the bactericidal activity of oxacillin. MBC checkerboards performed by 48-h subculture revealed antagonism with 37 strains (58%); in 26 additional strains (40%), a synergistic, additive, or indifferent effect was observed at low antibiotic concentrations, but antagonism was seen at higher concentrations. Time-kill studies tended to show indifference rather than antagonism with oxacillin plus rifampin. In checkerboards performed with oxacillin-resistant strains, the addition of rifampin did not improve oxacillin inhibitory or bactericidal activity to a clinically significant extent; however, the addition of oxacillin improved the bactericidal activity of rifampin at easily achievable serum concentrations.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6859835      PMCID: PMC184703          DOI: 10.1128/AAC.23.4.571

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Rifampin concentrations in cerebrospinal fluid of patients with tuberculous meningitis.

Authors:  J E Sippel; I A Mikhail; N I Girgis; H H Youssef
Journal:  Am Rev Respir Dis       Date:  1974-05

Review 2.  The use of combinations of antimicrobial drugs.

Authors:  E Jawetz
Journal:  Annu Rev Pharmacol       Date:  1968       Impact factor: 13.820

3.  Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies.

Authors:  G L Mandell; T K Vest
Journal:  J Infect Dis       Date:  1972-05       Impact factor: 5.226

4.  Bacteriologic studies of rifampin, a new semisynthetic antibiotic.

Authors:  C M Kunin; D Brandt; H Wood
Journal:  J Infect Dis       Date:  1969-02       Impact factor: 5.226

5.  Susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to 65 antibiotics.

Authors:  L D Sabath; C Garner; C Wilcox; M Finland
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

6.  Cerebrospinal fluid concentrations of rifampin in meningeal tuberculosis.

Authors:  J J D'Oliveira
Journal:  Am Rev Respir Dis       Date:  1972-09

7.  Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus.

Authors:  M A Sande; M L Johnson
Journal:  J Infect Dis       Date:  1975-04       Impact factor: 5.226

8.  Experimental osteomyelitis. IV. Therapeutic trials with rifampin alone and in combination with gentamicin, sisomicin, and cephalothin.

Authors:  C W Norden
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

9.  Rifampin therapy of Staphylococcus epidermidis. Use in infections from indwelling artificial devices.

Authors:  G L Archer; M J Tenenbaum; H B Haywood
Journal:  JAMA       Date:  1978-08-25       Impact factor: 56.272

10.  In vitro activity of rifampin alone and in combination with nafcillin and Vancomycin against pathogenic strains of Staphylococcus aureus.

Authors:  C U Tuazon; M Y Lin; J N Sheagren
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

View more
  8 in total

1.  Antagonistic effect of rifampin on the efficacy of high-dose levofloxacin in staphylococcal experimental foreign-body infection.

Authors:  O Murillo; M E Pachón; G Euba; R Verdaguer; F Tubau; C Cabellos; J Cabo; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

2.  Efficacy of high doses of levofloxacin in experimental foreign-body infection by methicillin-susceptible Staphylococcus aureus.

Authors:  O Murillo; A Doménech; A Garcia; F Tubau; C Cabellos; F Gudiol; J Ariza
Journal:  Antimicrob Agents Chemother       Date:  2006-10-02       Impact factor: 5.191

3.  Bactericidal activities of chloramphenicol and eleven other antibiotics against Salmonella spp.

Authors:  S R Preblud; C J Gill; J M Campos
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

Review 4.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

5.  [Synergism of ciprofloxacin with beta-lactam antibiotics, gentamicin, minocycline and pipemidic acid].

Authors:  N Dickgiesser; S in der Stroth; W Wundt
Journal:  Infection       Date:  1986 Mar-Apr       Impact factor: 3.553

6.  Antibiotic-specific differences in the response of Staphylococcus aureus to treatment with antimicrobials combined with manuka honey.

Authors:  Michael Liu; Jing Lu; Patrick Müller; Lynne Turnbull; Catherine M Burke; Ralf C Schlothauer; Dee A Carter; Cynthia B Whitchurch; Elizabeth J Harry
Journal:  Front Microbiol       Date:  2015-01-27       Impact factor: 5.640

7.  Synergism between Medihoney and rifampicin against methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  Patrick Müller; Dagmar G Alber; Lynne Turnbull; Ralf C Schlothauer; Dee A Carter; Cynthia B Whitchurch; Elizabeth J Harry
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240

8.  Combination of alpha-melanocyte stimulating hormone with conventional antibiotics against methicillin resistant Staphylococcus aureus.

Authors:  Madhuri Singh; Ravisekhar Gadepalli; Benu Dhawan; Kasturi Mukhopadhyay
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.